The Lancet regional health. Southeast Asia最新文献

{"title":"How can TB Mukt Panchayat initiative contribute towards ending tuberculosis in India?","authors":"Swathi Krishna Njarekkattuvalappil ,&nbsp;Hemant Deepak Shewade ,&nbsp;Parth Sharma ,&nbsp;Rakesh Purushothama Bhat Suseela ,&nbsp;Nandini Sharma","doi":"10.1016/j.lansea.2024.100376","DOIUrl":"10.1016/j.lansea.2024.100376","url":null,"abstract":"<div><p>Community Engagement (CE) for disease control and health has been tested for a long time across the globe for various health programmes. Realizing the need for true multisectoral action and CE and ownership for ending TB on an accelerated timeline, the Government of India launched a nationwide campaign for ‘TB <em>Mukt Panchayat’</em> (meaning ‘TB free village council’ in Hindi language) on 24 March 2023, banking on the system of local self-governments in the country. Though it is an initiative with huge potential to contribute to India’s efforts to end the TB epidemic, it is not without a few shortcomings. We critically analyse the TB <em>Mukt Panchayat</em> initiative and suggest a few recommendations for the way forward.</p></div>","PeriodicalId":75136,"journal":{"name":"The Lancet regional health. Southeast Asia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772368224000258/pdfft?md5=5b1db1b7e2d242f9bbc735657fda84b4&pid=1-s2.0-S2772368224000258-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140277221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research in cancer needs pivotal changes","authors":"The Lancet Regional Health – Southeast Asia","doi":"10.1016/j.lansea.2024.100421","DOIUrl":"https://doi.org/10.1016/j.lansea.2024.100421","url":null,"abstract":"","PeriodicalId":75136,"journal":{"name":"The Lancet regional health. Southeast Asia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772368224000714/pdfft?md5=a3bed949e09dfc6763786a70afe2e39b&pid=1-s2.0-S2772368224000714-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140901217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AI-based pipeline for early screening of lung cancer: integrating radiology, clinical, and genomics data","authors":"Ullas Batra ,&nbsp;Shrinidhi Nathany ,&nbsp;Swarsat Kaushik Nath ,&nbsp;Joslia T. Jose ,&nbsp;Trapti Sharma ,&nbsp;Preeti P ,&nbsp;Sunil Pasricha ,&nbsp;Mansi Sharma ,&nbsp;Nevidita Arambam ,&nbsp;Vrinda Khanna ,&nbsp;Abhishek Bansal ,&nbsp;Anurag Mehta ,&nbsp;Kamal Rawal","doi":"10.1016/j.lansea.2024.100352","DOIUrl":"10.1016/j.lansea.2024.100352","url":null,"abstract":"<div><h3>Background</h3><p>The prognosis of lung carcinoma has changed since the discovery of molecular targets and their specific drugs. Somatic Epidermal Growth Factor Receptor (<em>EGFR</em>) mutations have been reported in lung carcinoma, and these mutant proteins act as substrates for targeted therapies. However, in a resource-constrained country like India, panel-based next-generation sequencing cannot be made available to the population at large. Additional challenges such as adequacy of tissue in case of lung core biopsies and locating suitable tumour tissues as a result of innate intratumoral heterogeneity indicate the necessity of an AI-based end-to-end pipeline capable of automatically detecting and learning more effective lung nodule features from CT images and predicting the probability of the <em>EGFR</em>-mutant. This will help the oncologists and patients in resource-limited settings to achieve near-optimal care and appropriate therapy.</p></div><div><h3>Methods</h3><p>The <em>EGFR</em> gene sequencing and CT imaging data of 2277 patients with lung carcinoma were included from three cohorts in India and a White population cohort collected from TCIA. Another cohort LIDC-IDRI was used to train the AIPS-Nodule (AIPS-N) model for automatic detection and characterisation of lung nodules. We explored the value of combining the results of the AIPS-N with the clinical factors in the AIPS-Mutation (AIPS-M) model for predicting <em>EGFR</em> genotype, and it was evaluated by area under the curve (AUC).</p></div><div><h3>Findings</h3><p>AIPS-N achieved an average AP50 of 70.19% in detecting the location of nodules within the lung region of interest during validation and predicted the score of five lung nodule properties. The AIPS-M machine learning (ML) and deep learning (DL) models achieved AUCs ranging from 0.587 to 0.910.</p></div><div><h3>Interpretation</h3><p>The AIPS suggests that CT imaging combined with a fully automated lung-nodule analysis AI system can predict <em>EGFR</em> genotype and identify patients with an <em>EGFR</em> mutation in a cost-effective and non-invasive manner.</p></div><div><h3>Funding</h3><p>This work was supported by a grant provided by <span>Conquer Cancer Foundation of ASCO</span> [<span>2021IIG-5555960128</span>] and <span>Pfizer Products India Pvt. Ltd</span>.</p></div>","PeriodicalId":75136,"journal":{"name":"The Lancet regional health. Southeast Asia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772368224000027/pdfft?md5=e281698cbcb3d165c45528f425e086c3&pid=1-s2.0-S2772368224000027-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139876507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Association of high cortisol levels in pregnancy and altered fetal growth. Results from the MAASTHI, a prospective cohort study, Bengaluru” [The Lancet Regional Health – Southeast Asia 14 (2023) 100196]","authors":"Prafulla Shriyan ,&nbsp;Paulomi Sudhir ,&nbsp;Onno C.P. van Schayck ,&nbsp;Giridhara Rathnaiah Babu","doi":"10.1016/j.lansea.2024.100374","DOIUrl":"10.1016/j.lansea.2024.100374","url":null,"abstract":"","PeriodicalId":75136,"journal":{"name":"The Lancet regional health. Southeast Asia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772368224000234/pdfft?md5=dc79efaa9c64004c1d88cfc224c7dace&pid=1-s2.0-S2772368224000234-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140469965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Landscape of cancer clinical trials in India – a comprehensive analysis of the Clinical Trial Registry-India","authors":"Peng Gao ,&nbsp;Justin Chen ,&nbsp;Zhongyu Hong ,&nbsp;Marcus Choi ,&nbsp;Allison Morgan ,&nbsp;Anton Petushkov ,&nbsp;Rajuli Lall ,&nbsp;Chao Liu ,&nbsp;Vamshi K. Muddu ,&nbsp;Venugopal Arroju ,&nbsp;Chinnababu Sunkavalli ,&nbsp;Geoffrey Kim ,&nbsp;Bobby Y. Reddy","doi":"10.1016/j.lansea.2023.100323","DOIUrl":"10.1016/j.lansea.2023.100323","url":null,"abstract":"<div><h3>Background</h3><p>Cancer is one of the leading causes of morbidity and mortality in India. Clinical trials are critical for driving innovation in cancer therapy, diagnosis, and prevention. This study aims to depict the evolving landscape of cancer clinical trials in India by analysing the clinical trials registered in Clinical Trial Registry-India (CTRI).</p></div><div><h3>Methods</h3><p>We identified cancer trials registered in CTRI (between 2007 and 2021) using search terms adapted from the cancer types defined by the National Cancer Institute (USA). We then collated and analysed the publicly available information from CTRI (cancer subtypes, type of trial, treatment intent, type of intervention, sponsor type, recruitment countries) and used descriptive statistics to illustrate the overall as well as year-to-year trend.</p></div><div><h3>Findings</h3><p>In total, we identified 1988 cancer trials, the majority of which focused on treating cancer (63%) and rest of the trials aimed at optimising the operational aspects of surgery (19%), mitigating treatment-related toxicity (10.6%), or treating cancer-related symptoms (7.8%). Focusing on trials with the intent of treating cancer, we found that most were investigating solid tumours as opposed to haematological malignancies with the most prominent cancer subtypes being breast cancer (17%), head and neck cancer (9.8%), lung cancer (9.6%), and cervical cancer (6.6%). The number of trials conducted in a given cancer subtype from our analysis overall correlated to the incidence, mortality, and 5-year prevalence of the respective cancer subtype in India; however, head and neck cancer and cervical cancer were underrepresented in trials as compared with the disease burden. The most common type of intervention was investigational drugs. The most common sponsor types were global pharmaceutical industry (26%) and research institution and hospital (26%). Despite a relatively high cancer burden, the availability of cancer trials in the Northeastern states of India was limited.</p></div><div><h3>Interpretation</h3><p>There is a pressing need for clinical cancer research in India to be better aligned with the nation's healthcare needs and disease burden, focusing on prevalent and deadly cancers while ensuring the availability of clinical trials across geographic regions and underserved populations.</p></div><div><h3>Funding</h3><p><span>Pi Health USA</span>, a fully owned subsidiary of BeiGene Ltd.</p></div>","PeriodicalId":75136,"journal":{"name":"The Lancet regional health. Southeast Asia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S277236822300183X/pdfft?md5=a92fa8105f852addcf73381c27ccf449&pid=1-s2.0-S277236822300183X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135615076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Out-of-pocket payment and financial risk protection for breast cancer treatment: a prospective study from India","authors":"Tabassum Wadasadawala ,&nbsp;Sanjay K. Mohanty ,&nbsp;Soumendu Sen ,&nbsp;Tejaswi S. Kanala ,&nbsp;Suraj Maiti ,&nbsp;Namita Puchali ,&nbsp;Sudeep Gupta ,&nbsp;Rajiv Sarin ,&nbsp;Vani Parmar","doi":"10.1016/j.lansea.2023.100346","DOIUrl":"10.1016/j.lansea.2023.100346","url":null,"abstract":"<div><h3>Background</h3><p>Available data on cost of cancer treatment, out-of-pocket payment and reimbursement are limited in India. We estimated the treatment costs, out-of-pocket payment, and reimbursement in a cohort of breast cancer patients who sought treatment at a publicly funded tertiary cancer care hospital in India.</p></div><div><h3>Methods</h3><p>A prospective longitudinal study was conducted from June 2019 to March 2022 at Tata Memorial Centre (TMC), Mumbai. Data on expenditure during each visit of treatment was collected by a team of trained medical social workers. The primary outcome variables were total cost (TC) of treatment, out-of-pocket payment (OOP), and reimbursement. TC included cost incurred by breast cancer patients during treatment at TMC. OOP was defined as the total cost incurred at TMC less of reimbursement. Reimbursement was any form of financial assistance (cashless or repayment), including social health insurance, private health insurance, employee health schemes, and assistance from charitable trusts, received by the patients for breast cancer treatment.</p></div><div><h3>Findings</h3><p>Of the 500 patients included in the study, 45 discontinued treatment (due to financial or other reasons) and 26 died during treatment. The mean TC of breast cancer treatment was ₹258,095/US$3531 (95% CI: 238,225, 277,934). Direct medical cost (MC) accounted for 56.3% of the TC. Systemic therapy costs (₹50,869/US$696) were higher than radiotherapy (₹33,483/US$458) and surgery costs (₹25,075/US$343). About 74.4% patients availed some form of financial assistance at TMC; 8% patients received full reimbursement. The mean OOP for breast cancer treatment was ₹186,461/US$2551 (95% CI: 167,666, 205,257), accounting for 72.2% of the TC. Social health insurance (SHI) had a reasonable coverage (33.1%), followed by charitable trusts (29.6%), employee health insurance (5.1%), private health insurance (4.4%) and 25.6% had no reimbursement. But SHI covered only 40.1% of the TC of treatment compared to private health insurance that covered as much as 57.1% of it. Both TC and OOP were higher for patients who were younger, belonged to rural areas, had a comorbidity, were diagnosed at an advanced stage, and were from outside Maharashtra.</p></div><div><h3>Interpretation</h3><p>In India, the cost and OOP for breast cancer treatment are high and reimbursement for the treatment flows from multiple sources. Though many of the patients receive some form of reimbursement, it is insufficient to prevent high OOP. Hence both wider insurance coverage as well as higher cap of the insurance packages in the health insurance schemes is suggested. Allowing for the automatic inclusion of cancer treatment in SHI can mitigate the financial burden of cancer patients in India.</p></div><div><h3>Funding</h3><p>This work was funded by an extramural grant from the <span>Women’s Cancer Initiative</span> and the <span>Nag Foundation</span> and an intramural grant from the <","PeriodicalId":75136,"journal":{"name":"The Lancet regional health. Southeast Asia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772368223002068/pdfft?md5=cb05bca4331a5cfe4b8403841c006692&pid=1-s2.0-S2772368223002068-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139537783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Review of the India Adolescent Health Strategy in the context of disease burden among adolescentstitle of article” [The Lancet Regional Health – Southeast Asia 20 (2024) 100283]","authors":"Rakhi Dandona ,&nbsp;Anamika Pandey ,&nbsp;G Anil Kumar ,&nbsp;Monika Arora ,&nbsp;Lalit Dandona","doi":"10.1016/j.lansea.2024.100397","DOIUrl":"10.1016/j.lansea.2024.100397","url":null,"abstract":"","PeriodicalId":75136,"journal":{"name":"The Lancet regional health. Southeast Asia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772368224000477/pdfft?md5=4d3c6b4528fbb56e1014a7b8177f3b3c&pid=1-s2.0-S2772368224000477-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140763308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Author's reply – Out-of-pocket payment and financial risk protection for breast cancer treatment: a prospective study from India","authors":"Suraj Maiti ,&nbsp;Tejaswi S. Kanala ,&nbsp;Sanjay K. Mohanty ,&nbsp;Tabassum Wadasadawala","doi":"10.1016/j.lansea.2024.100391","DOIUrl":"10.1016/j.lansea.2024.100391","url":null,"abstract":"","PeriodicalId":75136,"journal":{"name":"The Lancet regional health. Southeast Asia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772368224000416/pdfft?md5=52b3d86da6987a84bdb7443b1e243724&pid=1-s2.0-S2772368224000416-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140279009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and evaluation of a training of trainers intervention for nursing professionals during COVID-19 pandemic in India","authors":"Maya Sahu ,&nbsp;Sailaxmi Gandhi ,&nbsp;Ravikant Pinjarkar ,&nbsp;Manjula M ,&nbsp;Paulomi M. Sudhir ,&nbsp;Rathi Balachandran","doi":"10.1016/j.lansea.2024.100413","DOIUrl":"https://doi.org/10.1016/j.lansea.2024.100413","url":null,"abstract":"","PeriodicalId":75136,"journal":{"name":"The Lancet regional health. Southeast Asia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772368224000635/pdfft?md5=64156e61a8050e26723ecb319dd32ab9&pid=1-s2.0-S2772368224000635-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140813366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Time for newer approach in age-old AIHA: Daratumumab?","authors":"Sigbjørn Berentsen ,&nbsp;Suvro Sankha Datta","doi":"10.1016/j.lansea.2024.100410","DOIUrl":"https://doi.org/10.1016/j.lansea.2024.100410","url":null,"abstract":"","PeriodicalId":75136,"journal":{"name":"The Lancet regional health. Southeast Asia","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S277236822400060X/pdfft?md5=1eb51f4cfa94f8cdbeaa8e4cc6bd4ef8&pid=1-s2.0-S277236822400060X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140637938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}